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The relationship of anaphylatoxin  to the complement system has  received 
increasing attention in the past few years. Osier et al.  (1)  observed a positive 
correlation between the activity of the third component of complement in rat 
serum and  the capacity of the serum to generate anaphylatoxin. Recently, a 
direct relation of anaphylatoxin with the complement system has been demon- 
strated through the use of purified components of complement. Dias da Silva 
and Lepow (2) have presented clear evidence that an agent with the full spec- 
trum of anaphylatoxin activities is dissociated from C"3 on interaction of Crl 
esterase with C'2,  C'3,  and C'4 in free solution. When C'5 was added to this 
system,  anaphylatoxin  activity was  neither augmented  nor diminished,  sug- 
gesting that C'5 was not essential for anaphylatoxin formation. In contrast to 
these  findings,  Jensen  (3),  working  with  functionally  purified  complement 
components of guinea pig serum,  related anaphylatoxin activity to  C'5,  and 
not  to  C'3.  This conclusion was drawn primarily from experiments in which 
anaphylatoxin was generated by treatment of functionally purified Ct5 either 
with trypsin or EAC'la, 4, 2a, 3, or with an anticomplementary factor of cobra 
venom. 
In view of these disparate conclusions as to the identity of anaphylatoxinogen 
in the guinea pig and human complement systems, we undertook experiments 
to examine if C~5 as well as C"3 could serve as parent molecules of anaphyla- 
toxin. Advantage was taken of the availability of highly purified components 
of human complement in this laboratory and of the possibility of introducing a 
radioactive label  into  these proteins.  In  addition,  use was  made  of  an  anti- 
* This is publication No. 246 from the Department of Experimental Pathology, Scripps 
Clinic and Research Foundation, La Jolla, Calif. The work was supported by United States 
Public Health Service Grant AI-07007, National Multiple Sclerosis Society Grant No. 459, 
American Heart Association Grant  65-G-166, and  Atomic Energy Commission Contract 
AJ(04-3)-410. Much of the data recorded was presented at the 51st Meeting of the American 
Association of Immunologists, April, 1967 (See  reference 17). 
:~ Established Investigator, The Helen Hay Whitney Foundation. 
371 372  ANAPHYLATOXIN AND  HUMAN COMPLEMENT 
complementary enzyme which constitutes  a  complex o/a  cobra venom protein 
and  a  j3-globulin of human  serum,  and  which  will be described  in detail  later. 
It was found that a low molecular weight fragment with anaphylatoxin  activity 
could be derived from both  C'3 and  C'5 and  that  the two  chemically distinct 
types  of  anaphylatoxin  differed  biologically and  with  respect  to  the  mode  of 
their production. 
Materials and Methods 
Nomenclature.--The nomenclature of complement components is that recommended at the 
complement workshop  of 1966  (4).  Numerical designations are given for each component. 
Complexes of erythrocytes (E), antibody (A), and components of complement (C') are desig- 
nated according to the reaction step achieved; e.g.,  EAC'I, EAC'I,4,  etc. Components re- 
quiring activation before becoming hemolytically active are given the small letter "a", such as 
C'2a, while components that have been inactivated are designated with "i",  such as C'3i. C~2 
that has been treated with iodine resulting in a 10-fold enhancement in activity is represented 
as °xYCt2 (5). 
Purified Components of Human  Complement.--C'l  esterase  was kindly supplied  by  Dr. 
Irwin Lepow. C'2 was isolated from human serum and oxydized with iodine by the method 
previously described (5). The preparation of C~3, C'4, and C'5 was the same as that previously 
reported  (6,  7, 8).  Labeling of C'3 and  C~5 with 126I was  performed by the chloramine T 
method (9), as described earlier (8, 10). 
Preparation of C~3 Inactivator Complex.--The  C 3-inactivating principle of cobra  venom 
was isolated from crude Naja naja venom as described (i1). In brief, venom is first  separated 
by Pevikon block electrophoresis in barbital buffer, pH 8.6, and the active material is  then 
further fractionated by filtration on Sephadex G-100 in tris buffer pH 7.6, 0.1% and 1 ~ NaC1. 
The active protein was shown to be homogeneous by polyacrylamide gel electrophoresis and 
by immunodiffusion analysis using a potent antiserum to whole snake venom (Behringwerke 
A. G., Marburg-Lahr,  West Germany).  Since the C'3 inactivator function of cobra venom 
factor depends upon the formation of a protein-protein complex with a human serum B-globu- 
fin  (11),  this  protein  was  also isolated,  x Starting  material  constituted  the pseudoglobulin 
fraction of human  serum which was fractionated in succession  by DEAE-cellulose chroma- 
tography, Pevikon block electrophoresis, and carboxymethyl (CM)-cellulose chromatography. 
The final product  is homogeneous by polyacrylamide gel electrophoresis. To form the C'3 
inactivator complex,  equlmolar amounts  of cobra  venom factor  (CoF)  and B-globulin  are 
mixed in the presence of  0.0005  M Mg  ++ and held for 10 rain at 37°C.  for  inactivation of 
C'3, incubation at 37°C for 20 rain with a small amount of complex, usually less  than  5% 
w/w, is sufficient. 
Generation of C~3-Converting Activity on Sensitized Erythrocytes and in Free Solution by C1, 
C'2, and C'4.--To obtain EAC'la,4,  °xy2 cells, sheep erythrocytes were sensitized by anti- 
body and exposed to Crl, C'4, and °~YC'2 as described earlier (10). C'(4,2)a in free solution 
was prepared as outlined previously (12). 
Preparation  of EAC%  °xy2,3  and  of  C~3i.--Usually,  20  ml  of  a  2.5%  suspension 
of EAC'la,4, °Xy2a cells were treated with EDTA (final concentration 0.01 ~) for 5 min at 
0°C  to dissociate Cqa. The cells were centrifuged and  resuspended  in 2 ml NaC1-Veronal 
buffer containing 0.01~ EDTA. They were then incubated at 32°C for 20 min with 1 mg CP3 
or C'3126I,  followed by sedimentation  by centrifugation.  Under these conditions,  approxi- 
mately 10% of the C'3 became cell-bound and 90% became converted to fluid phase C'3i. The 
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cells were washed three times with physiological saline to remove all unbound C'3, and they 
were then used for the treatment of C% The supernatant containing approximately 450 ~g 
C'3i/ml was immediately acidified to pH 3 using 0.5 ~ HC1 and was then subjected to Sephadex 
filtration or to anaphylatoxin activity studies. 
Detection of C'3 Conversion.--Conversion  of C'3 to C'3i was detected by immunoelectro- 
phoresis employing a specific antibody to C'3 (10). 
Measurement of C'5 Acti~ity.--C'5 activity was quantitated using EAC'4,  °Xy2a,3  cells 
and a 1:40 dilution of human serum treated with 1 M KSCN to which purified C'3 was added. 
The reaction was carried out in the presence of 0.01 st EDTA (8). 
Chromatography on Gds.--Separation of proteins was carried out on a column of Sephadex 
G-100 employing 0.01 -  sodium acetate buffer containing 0.15 st NaC1 at pH 4.0. Chromatog- 
raphy was performed at 4°C. Samples were layered between the buffer and the gel bed by first 
mixing  the  sample  with  sucrose  at  a  final  sucrose  concentration  of  10%. 
Density  Gradient Ultracentrifugcaion.--Linear  gradients  of  sucrose  were  prepared  on  a 
Buchler automatic density gradient device. Gradients of 7-31% sucrose were employed and 
linearity was verified by carbohydrate (anthrone) analysis of fractions. The sucrose contained 
0.15 st NaC1 and was buffered at pH 4.0 with 0.01 -  sodium acetate. Centrifugation was per- 
formed at 50,000 rpm and 4°C with an SW 50 rotor, using a  Spinco model L ultracentrifuge. 
Fractions were obtained dropwise from the bottom of each tube through a needle piercing the 
centrifuge tube. 
Contraction of Guinea Pig Ileum.--Tests of the capacity of various agents to evoke a con- 
traction of smooth muscle were assessed on the terminal ileum of guinea pigs. The data pre- 
sented represent examples of at least two and, most often, of five or more tests. Guinea pigs 
weighing 250-300 g were sacrificed, generally by cervical separation, and the terminal ileum 
carefully dissected from the mesentery. Only the lower 25 cm of ileum were employed. After 
thorough washing by passage of Tyrode's solution through the lumen, sections of approxi- 
mately 4 cm were cut and fixed by thread to a glass rod at one end and a kymograph lever at 
the other. The ileal strip was thus suspended in an 8 ml bath of Tyrode's solution maintained 
at 37°C with a gas mixture of 95% O3 and 5% COs passing through in fine bubbles. Atropine 
was added to a  final concentration of 10  -7 st. Each section employed was stimulated with 
histamine, generally starting with applications of 1 ~g (base) and terminating with 0.2/zg in 
order to achieve a state of replicable contractions to a standard stimulating concentration of 
histamine (1  X  10  -7 ~). The ileum was found to lose its capacity of responding to active 
preparations of anaphyiatoxin (human, guinea pig, or rat in origin) after about 1.5-2 hr time 
of removal. Hence all tests were performed on sections within 1.5 hr of sacrifice of the guinea 
pig. 
Mast Cell Preparations.--Rat mast ceils were obtained from  the peritoneal cavity of 200 g 
rats by modification of the  technique of Norton  (13).  6  ml medium  199  (Microbiological 
Associates, Albany, Calif.) was injected intraperitoneally into rats within 15 sec of cervical 
dislocation. The fluid was mixed in the cavity for 1-1.5 min and immediately aspirated. By 
diluting the ceil suspension obtained in the aspirated fluid with 5 ml of medium 199, clotting 
was avoided and an anticoagulant was not necessary. The cells were immediately centrifuged 
and washed four times in 5 ml volumes of medium 199 containing 1% purified gelatin. The 
resulting washed cell pellet was resuspended in 1.0 ml of medium 199-1% gelatin and cell 
counts obtained with a hemocytometer. Generally, 2 X  107 total ceils were obtained from each 
rat, about 4% of which were mast cells. 
Tests of Vascular Permeability.--These tests were performed in 300-350 g  male Hartley 
strain guinea pigs. Evan's blue, 0.5 ml of a  1% solution in isotonic saline, was injected intra- 
venously prior to testing. Testing samples were injected through No. 27 needles intradermally 
and the result was determined 20 rain later. Maximal and minimal diameters on the outer skin 
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same guinea pigs were employed within 30 rain of the first intradermal injections for evaluation 
of antihistamine inhibition of the permeability effect of tested solutions. Chlorpheniraznine 
maleate, 250 #g, was infused intravenously 10 min before further skin tests were performed. 
The absence of blueing caused by the intradermal injections of 1.0/zg histamine verified the 
effectiveness of antihistamine inhibition. 
Pkarmacologic Reagents.--Histamine hydrochioride was obtained from Eli Lilly and  Co., 
Indianapolis, Ind. Measurements are given according to the weight of histamine base. Chlor- 
pheniramine maleate (Chlor-Trimeton) was obtained from Schering Corp., Bloomfield, N. J., 
and bradykinin from Sandoz Co., Hanover, N. J. 
Anapkylatoxin Prepare~from Gu{nea  Pig Serum.--Fresh guinea pig serum (1.0 ml) was in- 
cubated with I0/~g CoF for 10 rain at 37°C.  The resulting active serum was maintained  at 
room temperature and used for tests within 2 hr. The same serum batch  untreated  by CoF 
failed to induce the various reactions reported below. 
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T~xT-Fm. 1.  Tracing produced by contraction of guinea pig ileum after two applications of 
150/~g C'5 treated with trypsin. H, histamine  1 X  10  -7 ~; T1, trypsinized  C'5; T2, guinea 
pig anaphylatoxin, 0.15 ml. 
RESULTS 
The Formation of a Factor from the Fiftk Component of Human  Complement 
Having Anaphylatoxin Activities 
Generation of Smooth Muscle--Contracting Capacity by Treatment with Trypsin. 
--150 #g C'5 was incubated with 3/zg trypsin at 32°C for 5 rain at pH  7.8. 
Soya bean trypsin inhibitor was added and the pH of the mixture adjusted to 
3.5  with 0.5  N HC1 and the total volume applied to the guinea pig ileum.  A 
strong contraction resulted (Fig. 1). Similarly, 80/~g C'5 after trypsinization as 
above evoked a contraction of moderate intensity. When a second application 
of the same dose of freshly trypsinized C'5 was added to the ileum, a marked 
reduction or complete absence of response resulted (Fig.  1). Application of as 
much as 180 #g untreated C'5,  trypsin, or trypsin inhibitor failed to yield a C.  G.  COCHRANE AND  tI.  J.  MULLER-EBERHARD  375 
contraction. A time-course experiment revealed that activity was not detecta- 
ble after 2.5 min of  trypsin treatment and that maximal activity yield was ob- 
tained after 5-10 min of treatment, after which time the yield decreased. Im- 
munoelectrophoretic analysis  of trypsin-treated C~5 showed partial conversion 
of C'5 to an electrophoretically faster migrating component (Fig.  2). 
Inhibition of Trypsinized C'5 Activity by Antihistamine.--Exposure  of  the 
T~xT-FIC. 2.  Immunoelectrophoretic demonstration of effect of trypsin on isolated human 
C%. Top, native CI5; bottom, C'5 treated with 2% (W/W) trypsin for 5 rain at 37°C. Patterns 
were developed with rabbit anti-human C%. 
guinea pig ileum to the antihistamine chlorpheniramine maleate 9.1  X  10  -7 ~t 
for 20  sec,  followed by removal of the  antihistamine  and  thorough washing, 
completely inhibited the capacity of 100 #g trypsinized C'5 and of 2 X  10-  s ~t 
histamine to evoke a contraction. Bradykinin, 2.2  ;4  10-  8 M, however, was able 
to induce contractions equal in amplitude to those obtained prior to treatment 
with antihistamine. 
Permeability Effect of Trypsinized C'5 in Guinea Pig Skin.--C'5 (125 #g/0.5 
ml) was treated with trypsin (2.50/~g)  for 12 min at 32°C.  At the end of the 
incubation time, soya bean trypsin inhibitor (SBTI)  (5.0 #g) was added, and 376  ANAPHYLATOXIN AND  HUMAN  COMPLEMENT 
the mixture,  along with control solutions, was injected intradermally into two 
guinea pigs previously given Evan's blue dye intravenously.  Injections of 0.1 
ml of the  incubated mixture  (25  #g trypsinized C'5)  induced  sites of blueing 
averaging 13 mm diameter, while the equivalent quantity of trypsin and SBTI 
gave sites of 3 mm diameter, and untreated  C'5 gaves sites of 2 mm diameter. 
When  injections  of  the  trypsinized  C~5  which  was kept  in  an  ice bath  were 
repeated over a period of 1 hr, the permeability inducing activity was found to 
diminish  so that  by 1 hr only a  trace of blueing was observed.  Injections of 
histamine (1 #g) during this period remained unchanged. 
Evidence  That the Smooth  Muscle-Contracting  Principle of C'5 is a Cleavage 
Product of the Parent Molecule.--In order to find if trypsin treatment of the C~5 
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TExT-Fla. 3.  Elution volume of trypsinized C'5, glucagon, protamine, and cytochrome c 
from a column of G-100 Sephadex, plotted as a function of molecular weight. The fraction of 
the trypsinized C% having the capacity of contracting guinea pig ileum is found in the mo- 
lecular weight range of 9,000-11,000. 
resulted  in  a  cleavage product having the  capacity of contracting guinea pig 
ileum, 3 mg C'5 was treated with 60/~g trypsin for 5 min at 32°C.  The pH of 
the mixture was then adjusted to 4.0 and the solution was applied to a column 
of  G-100  Sephadex.  Elution  was affected with  0.01  i  sodium  acetate  buffer, 
pH 4.0,  in  0.15  M NaC1.  The fractions obtained  were applied  directly  to  the 
atropinized guinea pig ileum.  Smooth muscle-contracting activity was present 
in  a  single  zone  eluting  immediately after  the  eluting  volume  (Ve)  of cyto- 
chrome c. When the Ve of the active principle and several other proteins used as 
markers were  plotted as a  function  of  the  logarithm  of molecular weights  as 
shown in Fig. 3,  the smooth muscle-contracting moiety of trypsinized C'5 was 
found to lie in  the molecular weight range of 9,000-11,000. 
Generation of Smooth Muscle-Contracting  Activity after Incubation  of CI5 with 
EACr4,  ' xy2a,3.--In  order to find  if smooth muscle-contracting activity could C.  G.  COCHRAIk~E AND  H. J.  MULLER-EBERHARD  377 
be derived from C'5 by exposure to the preformed washed intermediate complex 
EAC'4,°xy2a, 3, 180/~g  C'5 were treated with 2.5 X  109 cells in a  total volume 
of I  ml at 32°C for 15 rain. The supematant of this mixture was brought to 
pH 3.5 and tested on guinea pig ileum that had been made insensitive to C"3 
anaphylatoxin (see below). A contraction of moderate intensity followed. Tests 
of the supernatant revealed that only 15 % of the added C'5 had been inactivated 
by  treatment  with  EAC'4,°xy2a, 3.  When  such  a  supernatant  prepared 
identically was further treated with 3,6/~g trypsin for 5 min and then tested, 
greater smooth muscle-contracting activity was observed. C'5 (180 ~g) alone, 
as found previously, and C'5 (180 ~g) treated with EAC'4,°xy2a were unreactive 
H 
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TF.xT-FIG.  4.  Tracing produced by contraction of guinea pig ileum after  two  applictions 
of 200/~g C'3 treated with C 3 inactivator  complex (see text for details). H. histamine 1 X  10  -T 
M; T1, Ct3 inacfivator complex-treated C'3. 
In addition, incubation of washed EAC'4,°xy2a, 3 with saline rather than C'5 
failed to yield anaphylatoxin activity. 
The  Formation of Anaphylatoxin from  the  Third Component of Human 
Complement 
Formation of Anaphylatoxin from  C'3 by Cobra Factor-O-Globulin Complex 
(C'3 Inactivator).--Generation of anaphylatoxin from C'3 was attempted with 
C'3 inactivator complex (see Materials and Methods). Mter generation of the 
active complex, 200 #g C'3 was added and the mixture was held at 32°C  for 
20 rain before a  sample was removed for immunoelectrophoresis and the pH 
was adjusted to 4.0.  The sample was then applied to a  fresh guinea pig ileal 
strip; a strong contraction was observed (Fig. 4). Application of an identically 
prepared sample after washing of the ileal strip revealed complete desensitiza- 
tion, although the muscle was still fully reactive to histamine. Application of 378  ANAPHYLATOXII~  AND  HUMAN  COMPLEMENT 
untreated  C'3 or the C'3 inactivator complex failed to induce a  contraction. 
lmraunoelectrophoresis indicated the treated C'3 was completely converted to 
the more rapidly migrating component, C'3i. Treatment of 100/~g of C'5 with 
C'3 inactivator complex under similar conditions failed to produce anaphyla- 
toxin activity. 
Formation of Anaphylatoxin from C'3 by C'(4,°xy2)a  Complex.--C'3  (200/zg) 
was incubated with preformed C'(4,°xr2)a for 10 rain at 37°C. At the end of this 
period, the pH of the solution was immediately adjusted to 3.0 with 0.5 N HC1, 
and the entire contents of the tube added to the atropinized guinea pig ileum 
in a Schultz-Dale bath. A strong contraction followed the first application but 
did not occur on subsequent additions. Administration of C'3 alone or an identi- 
cal amount of C'(4,°xy2)a as noted above failed to induce a contraction. This 
confirmed the previous findings of Dias da Silva and Lepow (2)  that C'2 and 
C'4 in the presence of C'I esterase can generate anaphylatoxin from C'3 in free 
solution.  In  a  similar  experiment,  1.0  mg  C'3  was  incubated with  5  X  l0  t 
EAC'4,°xy2a cells for 20 rain at 32°C.  The cells were removed by centrifuga- 
tion, the pH of the supernatant adjusted to 3.5,  and aliquots added to a fresh 
strip of guinea pig ileum. Samples containing 100 ~g treated C'3 yielded nearly 
maximal  contraction,  while  aliquots  containing  60  tsg  C'3  after  incubation 
evoked  a  contraction equal  to  one-third  the  maximal  amplitude  and  40/zg 
treated  C'3  produced only a  small  deflection of the  recording needle.  Each 
aliquot was tested on a fresh ileal strip. Immunoelectrophoresis indicated com- 
plete conversion of the C'3 to the more rapidly migrating C'3i. 
Inhibition of Contraction by Antihistamine.--The  contraction brought about 
by C'3 inactivator complex-treated C'3 (200 #g) along with the response to rat 
anaphylatoxin was abolished when the ileum was exposed to 9 X  10  -7 M chlor- 
pheniramine maleate  (antihistamine)  for 20  sec and  then washed  repeatedly 
with Tyrode's solution.  Full  reactivity to 2.2  X  10  -s i  bradykinin was  still 
observed. 
ttistamine Release from Rat Mast Cells by C'3  Treated with C'3 Inactivator 
Complex.--Preparations  containing  C'3  (350  t~g) were  each  treated  with  a 
suitable amount of C'3 inactivator complex and placed on 2  ×  106 rat peri- 
toneal mast cells. Incubation was carried out for 1,  15, 30, 45, 60, and 90 rain 
at 37°C.  The cells were centrifuged and the supematant tested for histamine 
activity on guinea pig ileum. The ileum had previously been made tachyphy- 
lactic to C'3 anaphylatoxin. Histamine release was detectable after 1 rain incu- 
bation and reached a maximum between 45 and 60 rain of incubation. Samples 
containing 2 X  106 cells and C'3 (350 #g) alone or the C'3 inactivator complex 
did not possess measurable histamine. 
Permeability Reaction in Guinea Pig Skin by C'3 after Treatment with EAC'4, 
°*Y2a.--C'3 was  treated  with  EAC'4,°xy2a,  the  cells  were  removed  by  cen- 
trifugation, and the supernatant adjusted to pH 3.5. Immediately before injec- C. G.  COCHRANE  AND  H. J. MULLER-EBERHARD  379 
tion into the skin, the pH was brought to 7.0. Guinea pigs that previously had 
received Evan's  blue intravenously were injected intradermally with  50  and 
100 ~g  treated C'3.  Blueing at the injection sites of 4  and  7 mm diameters, 
respectively, occurred within 20 rain in each of two guinea pigs. Administration 
of C'3  alone in an equal amount failed to induce increased permeability. In 
addition,  pretreatment of the guinea pigs with  250/zg antihistamine  (chloro 
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~7~ 10 
.m 
~a  Ovalb.  Cyto.  C  Prot.  Glucal[on 
44ooo  12 ,oo 8o,oo  30oo 
Contraction  of 
30  40  50  60  70  80  90  100  110  120 1:30  Elution  Volume  (ml] 
TExT-Fro. 5. Elution of x25I C'3 treated with C'3 inactivator complex  from a column of 
Sephadex G-100. The fractions containing the factor capable of contracting guinea pig ileum 
are noted. Comparison  of the eluting volume  of the active material is compared with the elut- 
ing volumes  of ovalbumin (Ovalb.), cytochrome  c (Cyto C), protamine (Prot.), and glucagon. 
The molecular weight of each is noted. 
pheniramine maleate)  10 min before injection prevented development of the 
permeability reaction induced by treated C'3. 
Demonstration of a Fragment of C'3 Responsible  for Smooth Muscle Contraction 
after Treatment with C'3 Inactivator Complex.--Attempts were made to find ff 
the  C'3  inactivator complex cleaved a  fragment from C'3  that  possessed the 
capacity  to  induce  contraction of guinea  pig  ileum.  Accordingly, 5  mg  C'3 
labeled with 1~5I was treated with the f3-globulin-CoF complex. Mter 20 rain of 
incubation at'~ 32°C, the pH was adjusted to 3.0 with 0.5 N HC1 and the reaction 
mixture added to a column of Sephadex G-100 (1.3 X  28 cm) equilibrated with 
0.10 M NaC1 in 0.01 ~  Na acetate buffer of pH 4.0. Elution was carried out with 
the same buffer and fractions were tested directly on guinea pig ileum and the 380  ANAPHYLATOXIN  AND  HUMAIq COMPLEMENT 
results appear in Fig. 5. As noted,  three peaks of ~5I activity were eluted, one 
in the void volume (Vo), a  second eluting just after cytochrome c  (molecular 
weight  12,400),  and  a  third  immediately prior to  the internal volume of the 
column. Application of the various fractions to guinea pig ileum revealed that 
the  smooth  muscle-contracting  principle  was  contained  in  fractions  eluting 
with the second peak of 12hi activity (Fig. 5). This represented about 5 % of the 
total C'3. An estimate of the molecular weight of the smooth muscle-contracting 
principle was achieved by plotting the volumes of elution  (Ve) of this column 
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T~xT-FzG. 6.  Ultracentrffugation of zssI C'3 treated  with C~3 inactivator  complex in a 
density gradient. The pattern of treated z~sI  C'3 is compared with that of untreated  z25I  C'3 
and bovine serum albumin (BSA) that were centrifuged simultaneously. Fractions containing 
the material capable of inducing release of histamine from rat mast cells is noted by the con- 
traction of guinea pig ileum. Histamine released from the mast cells was detected only in 
fractions obtained from CP3 inactivator  complex-treated C'3. Conditions of centrifugation 
noted in Materials and Methods. 
as a function of the logarithm of molecular weights of various materials applied 
to it. By this procedure, the active material was detected in the range of molec- 
ular weights of from 6,000 to 17,000  using  bovine albumin, hen  egg albumin, 
cytochrome c,  protamine,  and glucagon as markers.  125I C'3 not treated with 
C'3 inactivator complex and containing no smooth muscle-contracting activity 
was also passed through a G-100 Sephadex column. A single peak of ~5I activity 
was obtained in  the void volume of the  column,  the  second and  third  peaks 
appearing after C'3 inactivator complex treatment did not appear. 
Density gradient ultracentrifugation of 200 #g untreated 125I C'3 is shown in 
Fig. 6. A rapidly sedimenting symmetrical peak of 125I activity was observed in 
both preparations, but only in the treated sample was mI activity found in the 
slowly sedimenting  fractions.  Assays were  carried  out  on 0.1  ml volumes of 
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As noted in Fig. 6, histamlne-releasing activity was found in only the slowly 
sedimenting fractions of the treated C'3. 
When labeled C'3 (500/~g)  was treated with the C'(4,°xy2)a complex in free 
solution and the pH adjusted to 5.0, an almost identical pattern of sedimenta- 
tion of the a~sI Ct3 was found. Again, histamine-releasing activity was associated 
with  the  C'3  sedimenting  slowly  in  the  gradient,  lmmunoelectrophoresis 
revealed that the C'3 was entirely converted to C'3i by C'(4,°xy2)a. 
Comparison of the Two Anaphylatoxin  Activities with Each Other and with 
Guinea Pig Anaphylatoxin 
Tests of Cross-Desensiti~tion  of Smooth Muscle  by the Active Materials  De- 
rived from C'5 and C'3.--A strip of guinea pig ileum was exposed twice to C'3 
(200 gg)  treated with CoF-fl-globulin complex.  The first strong contraction 
was followed by unresponsiveness with the second application. Exposure then 
to a minimal dose of C'5 (40 t~g), treated as before with trypsin, resulted in a 
contraction that was equal in intensity to that obtained by exposure of a fresh 
strip of ileum to the same dose of trypsinized C'5. Similarly, when a fresh guinea 
pig ileum segment was made unresponsive to trypsinized C'5 (two exposures to 
150 vg  trypsinized C'5),  the muscle was found  capable  of  responding fully 
to 150 ~g C'3 treated with CoF-fl-globulin complex. The response to histamine 
remained constant throughout. 
Tests of Cross-Desensiti~tion with the Two Smooth Muscle--Contracting Agents 
Derived from C'3.--Guinea pig ileum was made unresponsive to anaphylatoxin 
prepared from 200/~g C'3 by treatment with CoF-/3-globulin complex as noted 
above. C'4,°xy2a-treated C'3 (200/~g)  anaphylatoxin was then applied and no 
response followed. This unresponsiveness,  or crossed tachyphylaxis, also was 
observed when the ileal strip was made unresponsive in the reversed order of 
application. 
Relationship  of the Smooth Muscle-Contracting  Capacity of C'5  and  C'3  to 
Guinea Pig Anaphylatoxin.--With  the finding of Jensen that guinea pig C'5 
serves as anaphylatoxinogen (3), it was essential to find if a relationship exists 
between guinea pig and human C'5 anaphylatoxin. The data presented repre- 
sent the results of duplicate or triplicate experiments. Guinea pig anaphylatoxin 
was prepared and added to guinea pig ileum. A strong contraction followed and 
complete desensitization was noted after three additions to the ileal strip. When 
a minimal amount of trypsinized human C'5 (40 gg) was then applied, a mod- 
erate contraction resulted, the same magnitude as that obtained by addition 
of 40/zg of trypsin-treated C'5 to a  fresh ileal segment. In a  second, similar, 
experiment after the ileum was made unresponsive to guinea pig anaphylatoxin, 
addition of trypsin-treated C'5 (100 #g) brought about a maximal contraction. 
In the reverse order of application, 140/~g C'5 after treatment with trypsin was 
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complete desensitization to  a  second dose of identically prepared  C'5.  Sub- 
sequent addition of the CoF-treated guinea pig serum then resulted in a max- 
imal contraction, followed by desensitization after three applications as before 
(Fig.  1).  Each  ileal segment that had  been desensitized to the  CoF-treated 
guinea pig serum and trypsinized human C'5 reacted fully to human C'3 (200 
~g) that had been treated with EAC~4,°xy2a. 
The ileal-contracting capacity of the CoF-treated guinea pig serum was com- 
pletely inhibited by antihistamine  (9  X  10  -~  M chlorpheniramine maleate). 
The CoF-treated serum failed to contract rat uterus and induced release  of 
histamine from rat peritoneal mast cells; this latter activity did not occur with 
equal quantities of CoF alone or untreated guinea pig serum. The histamine 
assays were performed on guinea pig ileum previously made unresponsive to 
guinea pig anaphylatoxin (CoF-treated serum). 
DISCUSSION 
The data presented in this paper indicate that both C'3 and C'5 may serve 
as parent molecules of anaphylatoxin. They also show that the two anaphyla- 
toxins generated by complement differ from each other and from the guinea 
pig counterpart in biological reactivity. 
Treatment of C'5 with trypsin formed a product that induced contraction of 
guinea pig ileum and with repeated application to the ileum brought about a 
state of unresponsiveness (tachyphylaxis). The capacity to induce a contraction 
was inhibitable by antihistamine. Injection of the material intradermally in 
guinea pigs resulted in increased vascular permeability. The activity was also 
obtained by reacting C~5 with the intermediate erythrocyte-complement com- 
plex EAC'4,°xy2a, 3. As reported previously (8), this reaction results in binding 
to the cell surface of a small proportion of C'5 molecules and in loss of hemolytic 
activity of the majority of the molecules which remain in the fluid phase. That 
in the present experiments only 15 %  of the C'5  became inactivated is fully 
explained by the fact that the amount used constituted a large excess,  relative 
to the selected number of cells. Subsequent treatment with trypsin was expected 
to liberate more anaphylatoxin, as was observed, due to the availability of C~5 
which had  not reacted with  the  cells.  Although not yet demonstrated  con- 
clusively, it is probable that anaphylatoxin formation from C'5 coincides with 
abolition of hemolytic activity of C'5 by either trypsin or EAC'4,°xy2a, 3 cells. 
Apparently this cell-complement complex and the proteolytic enzyme exert a 
similar, if not identical, effect on the C'5 molecule. In fact, peptidase activity 
has been demonstrated to reside in cell-bound C'4,2a, 3 sites and is believed to 
depend upon a  critical spatial arrangement between the C'4,2a complex and 
C'3 (14, 15). In the cell free system employed by Dias da Silva and Lepow (2), 
addition  of  C~5  to  C'I  esterase,  C'4,  C'2,  and  C'3  neither  augmented  nor 
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the present study that the activity which resides in C~4, 2a, 3, and appears to 
be responsible for cleavage of C~5 is generated in much greater yield on a rela- 
tively stable surface such as a cell membrane than in free solution. 
As demonstrated above, brief treatment of C'5 with trypsin leads to cleavage 
of  the  molecule into  at  least  two fragments.  The  major  fragment,  readily 
detected by immunoelectrophoresis,  is  electrophoretically faster than  native 
C'5 and relative to the latter it is antigenically deficient.  The minor fragment, 
detected by gel filtration  through  its biological  activity, is  of low molecular 
weight (approximately 10,000) and constitutes C~5 derived anaphylatoxin.  In 
agreement  with  the  prevailing  principles  of  complement  nomenclature,  the 
active minor fragment  will henceforth  be denoted F(a)C'5  and  the inactive 
major fragment F(b)C'5. Although not investigated thus far, it may be assumed 
that  cell-bound C'4,2a, 3 produces the same changes  of the C~5 molecule.  In 
contrast, the C'3 converting enzyme (CP4,2a) and the C'3 inactivator complex, 
both capable of acting on C~3, appear to have no effect on C'5. 
Anaphylatoxin activity could also be derived from purified  C'3 by either of 
two different mechanisms.  It  was produced by incubation  with  the  C~3  in- 
activator complex which consists of a cobra venom protein and a thermolabile 
human  serum /~-globulin which  is  distinct  from any complement component 
(11). It  was also  produced upon  treatment  of C'3  with  the  C'3  converting 
enzyme generated from C~2 and Ct4 either in cell-free solution or on the surface 
of sensitized  erythrocytes. Both principles  had previously been shown to cause 
cleavage of the Ct3 molecule  (11, 16, 12) and it was found in  this  study that 
anaphylatoxin  activity resides  in  the low molecular weight fragment  (6,000- 
15,000) liberated from C~3 by either of the two enzymes.  That the two active 
products are similar  is suggested in the findings  that desensitization of guinea 
pig  Ileum  to  anaphylatoxin  produced  by C'3  treated  with  the  cobra factor 
inactivator complex resulted in loss of reactivity to anaphylatoxin derived from 
Cr4,2a-treated  C'3.  As will be reported later,  ~ a similar  low molecular weight 
fragment having anaphylatoxin activity could be obtained by treatment of Ct3 
with trypsin for 2 min at room temperature.  This fragment also cross-desensi- 
tizes the guinea  pig Ileum  to  C'3  anaphylatoxin  prepared  by the other  two 
methods.  Thus,  it  appears  that  cleavage  of  C'3  by several  enzymes  yields 
active fragments which so far are indistinguishable  from each  other by their 
biological  properties.  Following  a  suggestion  made by Dr.  Irwin Lepow, the 
active,  low molecular  weight  fragment  which  can  be derived from  C'3  will 
henceforth be called  F(a)C~3 and the residual,  larger  portion of the molecule 
F(b) C'3. 
The results reported in this paper confirm and extend pertinent observations 
made  by others  and  resolve  the  existing  discrepancy  as  to  the  identity  of 
anaphylatoxinogen.  Jensen  (3), working with guinea  pig complement,  attrib- 
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uted the capacity to donate anaphylatoxin activity solely to C'5. He was able 
to generate the activity both by trypsin and EAC'la, 4, 2a, 3 ceils. In addition, 
he found formation of the activity following treatment of serum fractions with 
partially purified CoF and again invoked C'5  as the  responsible component. 
Jensen's work appeared to preclude C~3 as potential donor of anaphylatoxin. 
On  the other hand,  Dias da Silva and Lepow (2)  clearly demonstrated that 
human C'3 can serve as anaphylatoxinogen, and that the activity arises upon 
treatment of Ct3 with CPl esterase, C'2, and CP4 in free solution. In this cell-free 
system, as discussed above, addition of Ct5 had no further effect on anaphyla- 
toxin activity. 
It may be safely concluded at this point that Jensen and Dias da Silva and 
Lepow worked with  two distinct anaphylatoxinogens and  that both C'3  and 
C'5 in human serum are capable of donating anaphylatoxin. The activities of 
human F(a)C~3 and F(a)C'5 appear to be quite different in view of their lack 
of cross-desensitization of guinea pig ileum as shown in the present studies. In 
addition, both failed to cross-desensitize to guinea pig anaphylatoxin, which has, 
in  unpublished  observations,  a  similar  molecular  weight  as  determined  by 
elution from Sephadex G-100. These data suggest that small but distinct struc- 
tural differences exist in the three types of anaphylatoxin studied.  Stegemann 
et al.  (17,  18,  19)  isolated anaphylatoxin from whole rat and pig serum and 
described properties that  resemble those of the  human  anaphylatoxins.  The 
identity of the parent molecule in these two cases, however, is unknown. 
Jensen's results with CoF, indicating that C'5 is affected by this agent, are 
inconsistent with  the finding reported here that  the  CP3 inactivator complex 
acts on human C'3 but not on human C'5. Species differences may account for 
this discrepancy which remains to be explained. 
Of great interest is the question of how the various anaphylatoxin molecules 
bring about the release of histamine from mast cells.  Studies are currently in 
progress  to  determine  whether  different  cells  are  attacked  by  each  agent, 
whether different sites are occupied on the same cells by the different anaphyla- 
toxins,  or whether different biochemical routes are  selected in  mast  cells  to 
bring about the release of histamine. 
SUM:MARY 
Anaphylatoxin activity was derived from both human C'5 and C'3 molecules. 
This was achieved in the case of C'5 by interaction with trypsin or with EAC'4, 
oxr2a, 3.  The smooth muscle-contracting material  obtained from the treated 
C'5  was  found  to  be  a  fragment  of  approximately 9,000-11,000  molecular 
weight. Its action was inhibited with antihistamine.  The trypsinized C'5 also 
increased vascular permeability in guinea pig skin. 
When human C'3 was incubated with C'3 inactlvator complex, which consists 
of a  cobra venom protein  and  a  fl-globulin of human  serum,  anaphylatoxin C.  G.  COCHRANE  AND  H.  J.  M-ULLER-EBERHARD  385 
activity was observed.  The activity was associated  with  a  fragment cleaved 
from the C~3 molecule, having a molecular weight of between 6,000 and 15,000 
as determined by gel filtration techniques.  Similar activity was derived from 
C'3 by the C'3-converting enzyme in free or in cell-bound form. 
The  C'5  anaphylatoxin failed  to  cross-desensitize  guinea  pig  ileum  to  the 
contracting  capacities  of  Ct3  and  guinea  pig  anaphylatoxin  and  vice versa. 
Anaphylatoxin prepared from C'3 by all methods mentioned above caused cross- 
desensitization to the other C~3 derivatives, but failed to desensitize to guinea 
pig anaphylatoxin. 
Note  Added  in Proof.--Dias  da Silva,  Eisele,  and  Lepow have published  studies 
describing  the formation and isolation of a cleavage product of human C'3, F(a)Ct3. 
The F(a)C'3 was split from the native molecule by the action of C'1 esterase,  C'2, 
and C'4. The isolated F(a)C'3, having a molecular weight of 6800 or less, exhibited 
all  the properties of anaphylatoxin previously recorded by these authors  (2).  (W. 
Dias da Silva,  J. W. Eisele,  and I. H. Lepow.  1967. Complement as a  mediator of 
inflammation. III. Purification  of the  activity with  anaphylatoxin properties gen- 
erated by interaction of the first four components of complement and its identifica- 
tion as a cleavage product of C~3. J. Exptl. Med. 126:1027.) 
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